Where Physician-Scientists' Clinical Insight Meets Venture Capital - Generating Healthcare Alpha.

PhysicianEstate is a healthcare venture capital firm built by physician-scientists. We invest in early-stage companies solving real clinical problems - from digital health platforms to medical devices to breakthrough therapeutics. Our network of 200+ physician LPs spans 20+ specialties and sits at the center of every investment decision.

We don't apply generic venture logic to healthcare. Our proprietary Discover, Diligence, Distribute framework sources deals from inside clinical workflows and research labs, validates them through physician-led multi-gate testing,and deploys our network as go-to-market advocates. That's not networking. That's structural advantage.

For Limited Partners For Founders
For Limited Partners For Founders

Our Investment Process

The DDD Framework - How Physician-Scientists Create Healthcare Alpha

  • The best healthcare companies are born where clinical problems meet scientific rigor. Traditional venture diligence misses what matters most in healthcare - clinical necessity, regulatory feasibility, and reimbursement viability.
  • These are the three forces that determine whether a healthcare company survives. Physician-scientist investors don't miss them. We embed clinical intelligence into every stage of the investment lifecycle.

01

Discover

  • Our physician network sources opportunities from research labs, academic medical centers, specialty conferences, and clinical workflows - places where problems get identified years before venture capitalists hear about them.
  • With 200+ physicians embedded at institutions like Johns Hopkins, Mayo Clinic, and Stanford, we find founders solving problems they've witnessed firsthand. This gives us a first look at the market's best healthcare opportunities, often at pre-institutional pricing.

02

Diligence

  • Three gates, three specialist layers. Gate one - clinical necessity: does 80%+ of our physician panel confirm this solves a real problem?
  • Gate two - regulatory and compliance feasibility: our advisors map the pathway - whether that's FDA clearance for drugs and devices, HIPAA and SOC 2 compliance for digital health, or health system procurement and credentialing requirements for service companies.
  • Gate three - reimbursement viability: our health economics specialists validate CPT/DRG coding, payer coverage strategy, and budget impact for health systems. By the time we commit capital, the regulatory and commercial guesswork has been eliminated.

03

Distribute

  • Physicians don't disappear after diligence. They become early users, clinical advisors, and procurement advocates across hospitals, clinics, and health systems.
  • Our network of 200+ specialists across 20+ disciplines is ready to champion portfolio companies into the care delivery ecosystem. Your customer acquisition problem becomes our network's clinical mission.
  • That built-in distribution pathway is what separates our companies from the rest.

Stage

Pre-Seed to Series A

Check Size

$100K - $5M

Focus

Healthcare & Life Sciences

Geography

Americas

Our Investment Focus

  • We invest across six healthcare subsectors - digital health, healthtech and services, devices and diagnostics, therapeutics, medtech and biotech platform tools, and specialty pharma. Within each, we apply the same filter: does this company improve patient outcomes, drive efficiency and cost savings, or enhance compliance and risk management?
  • Those three pillars define every investment decision. A company solving all three is exceptional. A company solving one exceptionally well gets our attention.
  • We back founders building healthcare's future - the ones who've seen the problems firsthand and have the credibility to solve them.

Our Portfolio

Where Clinical Conviction Meets Capital

Every investment below reflects our physician-led diligence process. Healthcare companies represent our core thesis - physician-scientists identifying clinical problems and funding the companies best positioned to solve them. We provide capital, clinical validation, regulatory guidance, and distribution through our physician network.

A last-mile inventory and logistics management platform for hospital systems.

Addressing a critical need in healthcare by improving regulatory compliance, reducing operational costs, and mitigating liability for hospitals.

A physical rehabilitation platform that helps employers prevent surgeries and treat employee pain at zero cost to them.

A dual-impact investment that reduces employer healthcare costs while enhancing employee well-being and productivity.

Developer of the first and only 6-lead, imperceptible wireless cardiac monitor for superior remote diagnostics.

Tapping into the high demand for advanced cardiac monitoring by offering a device with unsurpassed diagnostic value in a patient-friendly format.

Builds 40-gram micro-drones that uses ultrasonic sonar to detect and kill mosquitoes via kinetic interception.

Disrupting mosquito control with a chemical-free, autonomous low cost robotic solution, aiming to eradicate mosquitoes from human areas and saving millions of lives.

A patient acquisition platform that acts as an online directory for Direct Primary Care (DPC) and concierge healthcare providers in the US.

Direct care is gaining traction as the model cuts insurance overhead to offer affordable, accessible primary & specialty care to patients.

Builds autonomous stratospheric platforms for persistent aerial intelligence and telecommunications.

Unlocking the stratosphere as a critical new domain for defense and commercial infrastructure.

A decentralized cloud computing and energy marketplace.

An essential infrastructure play powering the explosive growth of AI and blockchain.

Builds core infrastructure for issuing and managing digital assets like RWAs and Stables.

Capitalizing on major regulatory and institutional tailwinds driving the proliferation of stablecoins and the tokenization of real-world assets (RWAs).

Develops kinetic payloads for missile defense. The system dispenses a cloud of unguided pellets (like "buckshot") to destroy targets via kinetic energy.

Wardstone makes missile defense economically sustainable and accurate against increasingly cheap and maneuverable threats like hypersonic missiles.

Company Name What It Does Our Macro Thesis
CAREier A last-mile inventory and logistics management platform for hospital systems. Addressing a critical need in healthcare by improving regulatory compliance, reducing operational costs, and mitigating liability for hospitals.
Aware Health A physical rehabilitation platform that helps employers prevent surgeries and treat employee pain at zero cost to them. A dual-impact investment that reduces employer healthcare costs while enhancing employee well-being and productivity.
WearLinq Developer of the first and only 6-lead, imperceptible wireless cardiac monitor for superior remote diagnostics. Tapping into the high demand for advanced cardiac monitoring by offering a device with unsurpassed diagnostic value in a patient-friendly format.
Tornyol Builds 40-gram micro-drones that uses ultrasonic sonar to detect and kill mosquitoes via kinetic interception. Disrupting mosquito control with a chemical-free, autonomous low cost robotic solution, aiming to eradicate mosquitoes from human areas and saving millions of lives.
FindMyDirectDoctor A patient acquisition platform that acts as an online directory for Direct Primary Care (DPC) and concierge healthcare providers in the US. Direct care is gaining traction as the model cuts insurance overhead to offer affordable, accessible primary & specialty care to patients.
Icarus Builds autonomous stratospheric platforms for persistent aerial intelligence and telecommunications. Unlocking the stratosphere as a critical new domain for defense and commercial infrastructure.
Akash Network A decentralized cloud computing and energy marketplace. An essential infrastructure play powering the explosive growth of AI and blockchain.
Noble Builds core infrastructure for issuing and managing digital assets like RWAs and Stables. Capitalizing on major regulatory and institutional tailwinds driving the proliferation of stablecoins and the tokenization of real-world assets (RWAs).
Wardstone Develops kinetic payloads for missile defense. The system dispenses a cloud of unguided pellets (like "buckshot") to destroy targets via kinetic energy. Wardstone makes missile defense economically sustainable and accurate against increasingly cheap and maneuverable threats like hypersonic missiles.
FG Communities Holdings (formerly FGNX) Acquires and operates land-lease affordable housing communities, after exiting its Ethereum treasury business. Manufactured housing is one of the last sources of unsubsidized affordable housing in the US, with steady, durable rental income.
Astrol Power Buys and builds US clean energy projects, including solar, battery storage and hybrid systems. An infrastructural investment capitalizing on the immense energy demands of the AI and high-performance computing sectors.
Zoqo (formerly YieldClub) Charting and analytics tools for prediction markets and event-driven trading. Prediction markets are becoming a mainstream way to price real-world events, and serious traders need professional data tools.
Acolite A licensed insurance broker for contractors that shops 10+ carriers on every submission. Small contractors still buy insurance through slow, paper-heavy brokers, and a tech-forward broker can win them on speed and choice.
Shred Finance Closed Wound down in 2026. Offered high-yield returns through delta-neutral, cross-chain strategies. High interest rates and thin crypto liquidity squeezed returns before it could scale, but we still believe demand for stable, high-yield products is real.

Our healthcare thesis sharpened over seven years of investing across sectors. As our physician network scaled past 200 members and our structural advantage in healthcare became undeniable, we leaned fully into what we do best. The investments above represent both our healthcare core and the broader portfolio foundation from which our healthcare practice evolved.

For Our Partners

Institutional-Grade Healthcare Investing,
Powered by Physician-Scientists.

01

Physician-Scientist Deal Flow

  • Most healthcare VCs see what's public. We see what works in the clinic first. Our network of 200+ physician LPs - embedded at research institutions, academic medical centers, and clinical frontlines across 20+ specialties - sources opportunities at the intersection of clinical need and market timing.
  • This structural advantage means we engage with founders when their science is proven, not theoretical. Before traditional venture channels surface them.

02

Multi-Gate Clinical and Regulatory Validation

  • Capital alone doesn't derisk healthcare. Our diligence process layers clinical necessity, regulatory pathway clarity, and payer reimbursement strategy on top of every market thesis. Physicians on our network review product science.
  • Ex-FDA advisors map regulatory pathways. Health economics specialists stress-test reimbursement assumptions. By the time we commit capital, we've eliminated the scientific and regulatory guesswork that sinks most early-stage healthcare investments.

03

Built-In Distribution

  • Post-investment, our physicians become more than advisors - they're early users, procurement advocates, and clinical champions within their hospitals, clinics, and health systems.
  • This built-in adoption pathway shortens the time from pilot to institutional revenue. It's de-risking that generalist funds simply cannot replicate, and it's why our portfolio companies reach commercial milestones faster.

04

Institutional-Grade Governance and Transparency

  • We operate with the rigor institutional LPs expect. Detailed reporting with portfolio performance and clinical milestone tracking. Direct GP access - no intermediaries between you and decision-makers.
  • Governance structures built for family offices, fund-of-funds, registered investment advisors, and institutional capital, alongside physician LPs who demand the same accountability. Radical transparency is non-negotiable.

For Healthcare Founders

Capital Plus Clinical Intelligence - What Your Healthcare Company Actually Needs to Scale.

01

Clinical Validation Before Market Entry

  • Your product may be clinically sound. But proving it with real physicians, real workflows, and real patient outcomes is what separates successful healthcare companies from well-funded failures.
  • Our 200+ physician-scientists validate your approach before you go to market. They identify adoption friction points early. They stress-test your clinical claims. They become your first users. By the time you're fundraising your next round, you're not selling a prototype - you're selling something physicians are already using.

02

Regulatory and Compliance Navigation

  • The path from regulatory clearance to care delivery adoption to payer coverage is where most healthcare startups stall.
  • For drugs and devices, we bring ex-FDA advisors who map your specific strategy - whether it's 510(k), De Novo, PMA, or SaMD classification.
  • For digital health and service companies, we navigate HIPAA compliance, SOC 2 certification, health system procurement processes, and credentialing requirements.
  • We connect you with health economics specialists who model your reimbursement pathway - CPT codes, DRG mapping, payer negotiation strategy. We don't guess at regulatory and compliance risk. We eliminate it with domain expertise your other investors don't have.

03

Clinical Distribution and Adoption at Scale

  • Closing one pilot is good. Scaling across 50 hospitals, clinics, and health systems is where generalist VCs go silent. We don't.
  • Our physicians become procurement advocates within their care delivery organizations. They champion adoption within their institutions. They drive peer recommendation across their specialties.
  • You get distribution through the actual settings where clinical decisions happen - not through generic vendor relationships. That turns early traction into institutional revenue.

Our Team

Harsha Moole, MD

Founding & Managing Partner

  • Harsha immigrated to the United States from India with a singular focus - advance patient outcomes. That mission shaped everything that came after. He earned his MD from Gandhi Medical College in India and trained as an Internal Medicine resident at the University of Illinois. As an inpatient hospitalist managing 3,000 to 3,500 patients annually, he developed the clinical instinct that comes from high-volume bedside work - the kind that teaches you what actually matters in patient care. That instinct led him to research. Over the next decade, he published 100+ peer-reviewed papers in journals including the New England Journal of Medicine and Gastroenterology, with his work incorporated into international patient guidelines, Harvard's UpToDate, and U.S. HHS federal resources. The U.S. government recognized the rigor with an EB-1A visa for extraordinary ability in medicine.
  • But research papers and bedside rounds had limits. Real impact on patient outcomes meant going direct - leveraging everything he knew about clinical science, unmet needs, and healthcare delivery into something bigger. He started making direct investments in healthcare companies, guided by a conviction that physician-scientists have a structural advantage in healthcare venture capital. They see the problems years before the market does. They understand regulatory and reimbursement complexity from the inside. They sit at the center of clinical adoption and distribution. No traditional venture investor can replicate that.
  • What started as a solo effort grew into what is now the only healthcare-specific venture capital group in the world that is end-to-end physician-scientist driven - from deal sourcing to diligence to post-investment distribution. Today, 200+ physician-scientists across 20+ specialties power the network. The portfolio spans 22 investments across digital health, devices, therapeutics, and services. He completed venture capital executive education at the Wharton School, University of Pennsylvania, to sharpen the investment craft.
  • Along the way, he founded FindMyDirectDoctor, a direct primary care marketplace that connected over 10,000 uninsured patients to affordable care and generated an estimated $120M+ in federal healthcare savings - work that earned the 2025 Kansas Business Innovation Merit Award from Governor Laura Kelly.
  • Today, Harsha's singular mission looks different on the surface - venture capital, physician networks, portfolio construction - but it's the same at the core. Put physician-scientists in position to identify, fund, and scale the companies solving the clinical problems they live every day. When he's not deep in diligence, he's playing basketball or driving to the Florida Keys with his family.
  • Dr. Haleem Mohammed (Dr. Hal), a Venture Partner at PhysicianEstate, offers a unique blend of expertise in finance, medicine, and executive leadership. Originally from India and raised in Brooklyn, he began his career on Wall Street as a Vice-President of Investments before earning his M.D. and an MBA from the University of Massachusetts.
  • He specializes in precision medicine and performance-driven wellness, focusing on cutting-edge solutions for longevity, hormone optimization, and musculoskeletal recovery. His distinguished career includes serving as Chief Medical Officer and Regional Medical Director for leading healthcare systems and clinical leadership for FIU Medical School's research foundation. Currently, he serves as the Global Chief Medical Officer for Gameday Men's Health, the largest concierge men's health network in North America.
  • He serves as a special government employee for the FDA and is a recognized Key Opinion Leader in concierge medicine. At PhysicianEstate, Dr. Hal leverages his extensive background to identify and cultivate early-stage healthcare ventures addressing real clinical and operational challenges. A decorated leader, he is the recipient of a 2024 Congressional Recognition, the 2024 CEO Healthcare Entrepreneur award, and the 2024 New Business of the Year award. Despite his professional success, he considers his most important role to be a husband and father, and in his mind, he's still just a kid from Brooklyn.

Haleem Mohammed, MD MBA

Venture Partner

Get in Touch

Whether you are an accredited investor interested in our thesis or a visionary founder building a category-defining company, our door is always open. We believe the best partnerships start with a simple conversation. Reach out to our team to connect.

Please do not paste links. We will ask for your deck by email.